Department of Urology, VU University Medical Centre, Amsterdam, The Netherlands.
Department of Urology, VU University Medical Centre, Amsterdam, The Netherlands.
Eur Urol. 2018 Sep;74(3):369-375. doi: 10.1016/j.eururo.2017.05.054. Epub 2017 Jun 12.
Robot-assisted laparoscopic (RAL) implantation of brachytherapy catheters (BTCs) can be a minimally invasive alternative to open retropubic implantation. Descriptions of the surgical technique and outcomes are sparse.
To describe our technique and perioperative outcomes for RAL BTC implantation in urothelial carcinoma (UC) and urachal carcinoma (UraC).
DESIGN, SETTING AND PARTICIPANTS: Between June 2011 and May 2016, 26 patients with cN0M0 solitary T1G3 or T2G1-3 UC of ≤5cm or cN0M0 UraC were scheduled for external beam radiotherapy (20×2Gy), RAL BTC implantation, and pulsed-dose (29×1.04Gy) or high-dose rate brachytherapy (10×2.50Gy). Median follow-up was 12 mo (interquartile range 4-20).
RAL BTC implantation with or without pelvic lymph node dissection and/or partial cystectomy.
Perioperative data, complications, disease-free-survival (DFS), local recurrence-free survival (LRFS), and cystectomy-free survival (CFS) were evaluated as well as the feasibility of the technique.
BTC implantation was successful in 92% of the patients. Median hospitalisation was 5 d (interquartile range 4-7) and blood loss <50ml in all cases. DFS was 74% at 1 yr and 63% at 2 yr. LRFS was 80% at 1 and 2 yr, and CFS was 87% at 1 and 2 yr. Early (≤30 d) high-grade complications (Clavien-Dindo ≥3) occurred in 8% of the patients. The study is limited by the small sample size and short follow-up time.
RAL BTC implantation is technically feasible and could serve as safe, minimally invasive alternative to open surgery in selected patients. The results of this study should be confirmed in larger studies.
Brachytherapy catheter (BTC) implantation is traditionally carried out via open retropubic surgery. We describe robot-assisted laparoscopic BTC implantation as a minimally invasive alternative. Perioperative outcomes are described and confirm the safety and feasibility of this procedure.
机器人辅助腹腔镜(RAL)植入近距离放射治疗导管(BTCs)可以作为一种微创选择,替代开放式经耻骨后植入。关于手术技术和结果的描述很少。
描述我们在尿路上皮癌(UC)和脐尿管癌(UraC)中进行 RAL BTC 植入的技术和围手术期结果。
设计、设置和参与者:2011 年 6 月至 2016 年 5 月期间,26 名 cN0M0 单发 T1G3 或 T2G1-3 UC 且肿瘤大小≤5cm 或 cN0M0 UraC 患者,计划接受外照射放疗(20×2Gy)、RAL BTC 植入以及脉冲剂量(29×1.04Gy)或高剂量率近距离放疗(10×2.50Gy)。中位随访时间为 12 个月(四分位距 4-20)。
RAL BTC 植入术,联合或不联合盆腔淋巴结清扫术和/或部分膀胱切除术。
评估围手术期数据、并发症、无疾病生存(DFS)、局部无复发生存(LRFS)和无膀胱切除术生存(CFS),以及该技术的可行性。
92%的患者成功进行了 BTC 植入。中位住院时间为 5 天(四分位距 4-7),所有患者的失血量均<50ml。1 年时 DFS 为 74%,2 年时为 63%。1 年和 2 年时 LRFS 分别为 80%和 87%,1 年和 2 年时 CFS 分别为 87%和 87%。8%的患者出现早期(≤30 天)高等级并发症(Clavien-Dindo ≥3)。该研究的局限性在于样本量小且随访时间短。
RAL BTC 植入术在技术上是可行的,并且可以作为一种安全、微创的选择,替代选定患者的开放式手术。这些研究结果应在更大的研究中得到证实。
BTC 植入传统上通过开放式经耻骨后手术进行。我们描述了机器人辅助腹腔镜 BTC 植入作为一种微创替代方法。描述了围手术期结果,证实了该手术的安全性和可行性。